Opendata, web and dolomites

GLIOMA

Targeting Glioblastoma using Combinatorial Therapeutic Nanovaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLIOMA project word cloud

Explore the words cloud of the GLIOMA project. It provides you a very rough idea of what is the project "GLIOMA" about.

holds    functionalised    tmz    nanoparticles    extremophilic    performed    modules    nvax    binding    activation    subjected    tnvax    vitro    site    characterisation    lines    antibody    permanently    interactions    multiforme    bacterial    synthesis    appropriate    gbm    temozolamide    patients    memory    killing    particles    characterised    synthesised    eradicating    pharmacokinetic    techniques    microscopic    thereby    significantly    recognizes    monoclonal    facilitates    cells    suppression    chemo    macrophage    murine    payload    core    mauran    immunological    suffer    outcomes    pharmacodynamic    multiple    examinations    coated    nanovaccine    encapsulated    tumour    anti    immunofluorescence    immune    encapsulating    alter    induction    drug    caused    histopathological    nanocage    good    therapeutic    formulation    cytotoxicity    immuno    polysaccharide    models    combinatorial    cell    offers    host    vivo    cytokine    cd133    channel    gold    l1    kinetics    glioblastoma    release    therapeutically    spectroscopic    stimulate    disease    pd    antigen    nps    contain    evaluations    amount    facs    leaving    functionalisation    antitumour   

Project "GLIOMA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF BRIGHTON 

Organization address
address: LEWES ROAD MITHRAS HOUSE
city: BRIGHTON
postcode: BN2 4AT
website: www.brighton.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.brighton.ac.uk/research-and-enterprise/groups/biomaterials-and-medical-devices/glioma.aspx
 Total cost 195˙454 €
 EC max contribution 195˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-10-02   to  2019-10-01

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF BRIGHTON UK (BRIGHTON) coordinator 195˙454.00

Map

 Project objective

The proposal aims at the synthesis, characterisation and application of a novel therapeutic nanovaccine (TNVax) that holds multiple modules for targeting glioblastoma multiforme (GBM). The proposed TNVax formulation includes a gold nanocage core encapsulating Temozolamide (TMZ), coated with an extremophilic bacterial polysaccharide, mauran functionalised with anti-PD-L1 antibody and anti-CD133 antibody. The us of NVax nanoparticles (NPs) offers a combinatorial approach in killing GBM cells both by immuno- and chemo- therapeutically. Site-specific delivery of the payload will stimulate the host immune system and channel the immune cells to the target site. Functionalisation of the anti-PD-L1 antibody on drug-encapsulated NPs would significantly alter the immune suppression caused by GBM cells on TNVax delivery. In addition to anti-PD-L1 antibody, the TNVax particles contain tumour specific monoclonal antibody that specifically recognizes CD133 antigen and facilitates strong binding. This approach would enhance the amount of antitumour activity offered by multiple means and thereby leaving a strong immune response against GBM based on antigen-antibody interactions. TNVax NPs will be synthesised and characterised using microscopic and spectroscopic techniques and then subjected to in vitro and in vivo evaluations. In vitro studies will be performed for drug release kinetics and cytotoxicity using immunofluorescence and FACS analysis. Induction of immune response by TNVax NPs will be evaluated using macrophage activation, induction of T-cell activity and cytokine production under in vitro conditions. The pharmacokinetic and pharmacodynamic studies will be carried out and histopathological examinations performed using appropriate murine models induced with GBM cell lines. The potential outcomes of the proposed studies will help patients who suffer from early and advanced GBM by eradicating the disease permanently and leaving good immunological memory.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More